Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Abeona Therapeutics Inc is a biotechnology business based in the US. Abeona Therapeutics shares (ABEO) are listed on the NASDAQ and all prices are listed in US Dollars. Abeona Therapeutics employs 90 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $0.19 |
|---|---|
| 52-week range | $0.13 - $1.56 |
| 50-day moving average | $0.18 |
| 200-day moving average | $0.45 |
| Wall St. target price | $2.33 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.81 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.19 from 2022-07-01
| 1 week (2022-06-28) | 3.15% |
|---|---|
| 1 month (2022-06-01) | 22.50% |
| 3 months (2022-04-05) | -44.30% |
| 6 months (2022-01-05) | -40.68% |
| 1 year (2021-07-02) | -87.74% |
|---|---|
| 2 years (2020-07-02) | -93.33% |
| 3 years (2019-07-05) | 4.56 |
| 5 years (2017-07-05) | 7.3 |
| Revenue TTM | $3.3 million |
|---|---|
| Gross profit TTM | $-299,000 |
| Return on assets TTM | -36.37% |
| Return on equity TTM | -142.61% |
| Profit margin | 0% |
| Book value | $0.21 |
| Market capitalisation | $30.6 million |
TTM: trailing 12 months
We're not expecting Abeona Therapeutics to pay a dividend over the next 12 months.
Abeona Therapeutics's shares were split on a 1:50 basis on 23 October 2014. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Abeona Therapeutics shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Abeona Therapeutics shares which in turn could have impacted Abeona Therapeutics's share price.
Over the last 12 months, Abeona Therapeutics's shares have ranged in value from as little as $0.13 up to $1.56. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Abeona Therapeutics's is 1.5. This would suggest that Abeona Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Abeona Therapeutics Inc. , a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.